UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia

Journal of thrombosis and haemostasis, 2017-06, Vol.15 (6), p.1103-1105

Berntorp, E.

2017

Volltextzugriff (PDF)

Replacement therapy during surgery in von Willebrand disease needs personalization

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.338-340

Berntorp, E.

2018

Volltextzugriff (PDF)

Haemophilia treatment in 2030

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (S5), p.15-19

Berntorp, E.

2016

Volltextzugriff (PDF)

Future of haemophilia outcome assessment: registries are key to optimized treatment

Journal of internal medicine, 2016-06, Vol.279 (6), p.498-501

Berntorp, E.

2016

Volltextzugriff (PDF)

Defining extended half‐life rFVIII—A critical review of the evidence

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.348-358

2018

Volltextzugriff (PDF)

Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-01, Vol.15 (1), p.3-10

BERNTORP, E.

2009

Volltextzugriff (PDF)

Immune tolerance induction: What have we learned over time?

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-04, Vol.24 (S3), p.3-14

2018

Volltextzugriff (PDF)

Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-11, Vol.15 (6), p.1219-1227

BERNTORP, E.

2009

Volltextzugriff (PDF)

Inhibitors in haemophilia: what have we learned from registries? A systematic review

Journal of internal medicine, 2015-01, Vol.277 (1), p.1-15

2015

Volltextzugriff (PDF)

Registry‐based outcome assessment in haemophilia: a scoping study to explore the available evidence

Journal of internal medicine, 2016-06, Vol.279 (6), p.502-514

2016

Volltextzugriff (PDF)

Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-11, Vol.19 (6), p.805-807

Berntorp, E.

2013

Volltextzugriff (PDF)

Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-01, Vol.15 (1), p.122-130

2009

Volltextzugriff (PDF)

History of prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-03, Vol.19 (2), p.163-165

Berntorp, E.

2013

Volltextzugriff (PDF)

Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualization

Journal of thrombosis and haemostasis, 2016-04, Vol.14 (4), p.724-732

2016

Volltextzugriff (PDF)

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.514-520

2016

Volltextzugriff (PDF)

Preference‐based valuation of treatment attributes in haemophilia A using web survey

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-11, Vol.23 (6), p.894-903

2017

Volltextzugriff (PDF)

Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network

Journal of thrombosis and haemostasis, 2015-09, Vol.13 (9), p.1585-1589

2015

Volltextzugriff (PDF)

Bleeding‐related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.628-633

2018

Volltextzugriff (PDF)

Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study

Thrombosis research, 2019-09, Vol.181 (Sept.), p.106-111

2019

Volltextzugriff (PDF)

Joint comorbidities among Swedish carriers of haemophilia: A register‐based cohort study over 22 years

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-09, Vol.25 (5), p.845-850

2019

Volltextzugriff (PDF)

No difference in quality of life between persons with severe haemophilia A and B

Haemophilia : the official journal of the World Federation of Hemophilia, 2023-07, Vol.29 (4), p.987-996

2023

Volltextzugriff (PDF)

Prophylaxis in von Willebrand disease

Haemophilia : the official journal of the World Federation of Hemophilia, 2008-11, Vol.14 (s5), p.47-53

BERNTORP, E.

2008

Volltextzugriff (PDF)

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-05, Vol.22 (3), p.389-396

2016

Volltextzugriff (PDF)

Factor IX antibodies and tolerance in hemophilia B in the Nordic countries – The impact of F9 variants and complications

Thrombosis research, 2022-09, Vol.217, p.22-32

2022

Volltextzugriff (PDF)

Quality of life in adult patients with haemophilia - a single centre experience from Sweden

Haemophilia : the official journal of the World Federation of Hemophilia, 2012-07, Vol.18 (4), p.527-531

2012

Volltextzugriff (PDF)

1 – 25 von 679

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(402)
Mit Volltextzugriff
(434)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia

Replacement therapy during surgery in von Willebrand disease needs personalization

Haemophilia treatment in 2030

Future of haemophilia outcome assessment: registries are key to optimized treatment

Defining extended half‐life rFVIII—A critical review of the evidence

Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

Immune tolerance induction: What have we learned over time?

Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens

Inhibitors in haemophilia: what have we learned from registries? A systematic review

Registry‐based outcome assessment in haemophilia: a scoping study to explore the available evidence

Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study

Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate®, a new generation von Willebrand factor/factor VIII concentrate

History of prophylaxis

Population pharmacokinetics of plasma‐derived factor IX: procedures for dose individualization

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

Preference‐based valuation of treatment attributes in haemophilia A using web survey

Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network

Bleeding‐related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network

Hypertension and cardiovascular diseases in Swedish persons with haemophilia — A longitudinal registry study

Joint comorbidities among Swedish carriers of haemophilia: A register‐based cohort study over 22 years

No difference in quality of life between persons with severe haemophilia A and B

Prophylaxis in von Willebrand disease

Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc

Factor IX antibodies and tolerance in hemophilia B in the Nordic countries – The impact of F9 variants and complications

Quality of life in adult patients with haemophilia - a single centre experience from Sweden

Suchergebnisse filtern